Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    31-October-2000      
Issue 201 Next Update - 14:00 UTC 08:00 EST    01-November-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Renal Safety Profile of Vioxx® Confirmed

Vioxx Has Renal Safety Profile Similar To That Of Certain Non-Steroidal Anti-Inflammatory Drugs

In an analysis presented at the European League Against Rheumatism (EULAR), the renal safety profile of Vioxx(R) (rofecoxib) was not statistically different from celecoxib. In a separate analysis, Vioxx had a renal safety profile that is similar to that of certain non-steroidal anti-inflammatory drugs (NSAIDs), Merck & Co., Inc. confirmed today in response to a news release by a competitor. Vioxx is Merck's medicine for osteoarthritis and acute pain.

In a new study presented at EULAR that evaluated the efficacy of Vioxx 12.5 mg once-daily, Vioxx 25 mg once-daily, celecoxib 200 mg once-daily and acetaminophen 1,000 mg four-times daily in 382 patients with osteoarthritis, Vioxx 25 mg was superior to celecoxib at relieving osteoarthritis pain at night and at rest. Further data from this study, which was the subject of a separate release, showed that all treatments were well tolerated. There were no significant differences in the incidence of any adverse events between treatment groups and there were no significant differences in the number of patients who stopped participating in the study due to adverse experiences. Of the 382 patients in this study, 160 (41 percent) had a history of hypertension.

In particular, there were no significant differences in the incidence of renal effects, such as hypertension and edema, and no significant differences in the number of patients who stopped participating in the study due to renal effects.

The renal safety profile of Vioxx also was demonstrated in Phase III osteoarthritis safety and efficacy trials involving more than 4,000 patients. In these studies, 2,829 patients took Vioxx (12.5 mg or 25 mg, the doses approved for osteoarthritis), 847 patients took ibuprofen 2,400 mg and 498 took diclofenac 150 mg. The average age of patients was 63, and 39 percent had a history of hypertension. These trials lasted up to 12 months.

In these studies, the incidences of increased blood pressure and lower extremity edema among patients taking Vioxx were similar to those of the comparator NSAIDs; there were no significant differences between the active treatment groups.

* Edema: 3.4 to 3.8 percent of patients taking either Vioxx or one of the comparator NSAIDs reported lower extremity edema. Most patients reported that the edema resolved while they continued to take their medicine, and few patients (no more than 0.4 percent in any treatment group) stopped taking their medicine because of edema.

* Blood pressure: The mean change in blood pressure among patients who were taking either Vioxx or one of the comparator NSAIDs was negligible, with a range of 1.1 mm decrease to a 1.1 mm increase in diastolic blood pressure and a range of 0.7 mm increase to a 2 mm increase in systolic blood pressure. Most cases of hypertension were mild and resolved while patients continued to take the medicines; few patients (no more than 0.4 percent of patients in any treatment group) stopped taking their medicine because of hypertension.

An additional study compared the renal effects of Vioxx 12.5 mg and 25 mg to another comparator NSAID, indomethacin 150 mg, and placebo in 57 elderly patients. In this study, there was no significant difference between Vioxx or indomethacin and placebo in measures of renal function (glomerular filtration rate, serum creatinine, serum electrolytes and blood pressure).


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.